Clinical value of antibodies in inflammatory bowel diseases
- Authors: Aleksandrova E.N.1, Novikov A.A.1, Lukina G.V.1, Parfenov A.I.1
-
Affiliations:
- Loginov Moscow Clinical Research and Practical Center
- Issue: Vol 93, No 2 (2021)
- Pages: 228-235
- Section: Reviews
- URL: https://journals.rcsi.science/0040-3660/article/view/64782
- DOI: https://doi.org/10.26442/00403660.2021.02.200610
- ID: 64782
Cite item
Full Text
Abstract
Inflammatory bowel disease – IBD (Crohn’s disease – CD, ulcerative colitis – UC) – immune-mediated diseases of the digestive tract of unknown etiology. The basis of the pathogenesis of IBD is a violation of the protective mechanisms of the intestinal barrier as a result of a complex interaction of environmental factors, a genetic predisposition and defects in the activation of the immune response in the lymphoid tissue of the intestinal mucosa. Three groups of antibodies are detected in the sera of IBD patients: autoantibodies, antimicrobial antibodies and antibodies to peptide antigens. In CD, the most useful diagnostic markers are ASCA; in UC patients – pANCA. Antibodies are not among the diagnostic criteria for CD and UC, the diagnosis of which is traditionally made on the basis of a complex of clinical, radiological, endoscopic and histological signs, but can be used as useful additional non-invasive markers for early diagnosis, assessment of clinical phenotypes, prognosis and effectiveness of treatment of these diseases.
Full Text
##article.viewOnOriginalSite##About the authors
E. N. Aleksandrova
Loginov Moscow Clinical Research and Practical Center
Email: asfold@mail.ru
ORCID iD: 0000-0003-4074-5907
д.м.н., зав. лаб. клинической иммунологии
Russian Federation, MoscowA. A. Novikov
Loginov Moscow Clinical Research and Practical Center
Email: asfold@mail.ru
ORCID iD: 0000-0002-2738-2956
д.б.н., вед. науч. сотр. лаб. клинической иммунологии
Russian Federation, MoscowG. V. Lukina
Loginov Moscow Clinical Research and Practical Center
Email: asfold@mail.ru
ORCID iD: 0000-0001-7958-5926
д.м.н., проф., зав. отд. ревматологии
Russian Federation, MoscowA. I. Parfenov
Loginov Moscow Clinical Research and Practical Center
Author for correspondence.
Email: asfold@mail.ru
ORCID iD: 0000-0002-9782-4860
д.м.н., проф., зав. отд. патологии кишечника
Russian Federation, MoscowReferences
- Клинические рекомендации по диагностике и лечению болезни Крона у взрослых (проект). Колопроктология. 2020;19(2):8-38 [Crohn’s disease. Clinical recommendations (preliminary version). Koloproktologia. 2020;19(2):8-38 (In Russ.)]. doi: 10.33878/2073-7556-2020-19-2-8-38
- Ивашкин В.Т., Шелыгин Ю.А., Халиф И.Л. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению язвенного колита. Колопроктология. 2017;1:6-30 [Ivashkin VT, Shelygin IuA, Khalif IL, et al. Clinical guide of Russian association of gastroenterology and Russian association of coloproctology on diagnostics and treatment of ulcerative colitis. Koloproktologia. 2017;1:6-30 (In Russ.)].
- Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474(7351):307-17. doi: 10.1038/nature10209
- Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491(7422):119-24. doi: 10.1038/nature11582
- McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3(8):e297. doi: 10.1371/journal.pmed.0030297
- Kayama H, Takeda K. Functions of innate immune cells and commensal bacteria in gut homeostasis. J Biochem. 2016;159(2):141-9. doi: 10.1093/jb/mvv119
- Choy MC, Visvanathan K, De Cruz P. An Overview of the innate and adaptive immune system in inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(1):2-13. doi: 10.1097/MIB.0000000000000955
- Norouzinia M, Chaleshi V, Alizadeh AHM, Zali MR. Biomarkers in inflammatory bowel diseases: insight into diagnosis, prognosis and treatment. Gastroenterol Hepatol Bed Bench. 2017;10(3):155-167
- Mitsuyama K, Niwa M, Takedatsu H, et al. Antibody markers in the diagnosis of inflammatory bowel disease. World J Gastroenterol. 2016;22(3):1304-10. doi: 10.3748/wjg.v22.i3.1304
- Bossuyt X. Serologic markers in inflammatory bowel disease. Clin Chem. 2006;52(2):171-81. doi: 10.1373/clinchem.2005.058560
- Dotan I. New serologic markers for inflammatory bowel disease diagnosis. Dig Dis. 2010;28(3):418-23. doi: 10.1159/000320396
- Kuna AT. Serological markers of inflammatory bowel disease. Biochem Med (Zagreb). 2013;23(1):28-42. doi: 10.11613/bm.2013.006
- Kovács M, Müller KE, Papp M, et al. New serological markers in pediatric patients with inflammatory bowel disease. World J Gastroenterol. 2014;20(17):4873-82. doi: 10.3748/wjg.v20.i17.4873
- Arai R. Serologic markers: impact on early diagnosis and disease stratification in inflammatory bowel disease. Postgrad Med. 2010;122(4):177-85. doi: 10.3810/pgm.2010.07.2184
- Prideaux L, De Cruz P, Ng SC, Kamm MA. Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2012;18(7):1340-55. doi: 10.1002/ibd.21903
- Bonneau J, Dumestre-Perard C, Rinaudo-Gaujous M, et al. Systematic review: new serological markers (anti-glycan, anti-GP2, anti-GM-CSF Ab) in the prediction of IBD patient outcomes. Autoimmun Rev. 2015;14(3):231-45. doi: 10.1016/j.autrev.2014.11.004
- Peyrin-Biroulet L, Standaert-Vitse A, Branche J, Chamaillard M. IBD serological panels: facts and perspectives. Inflamm Bowel Dis. 2007;13(12):1561-6. doi: 10.1002/ibd.20226
- Mukhtyar C, Flossmann O, Hellmich B, et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis. 2008; 67:1004-10. doi: 10.1136/ard.2007.071936
- Desplat-Jégo S, Johanet C, Escande A, et al. Update on Anti-Saccharomyces cerevisiae antibodies, anti-nuclear associated anti-neutrophil antibodies and antibodies to exocrine pancreas detected by indirect immunofluorescence as biomarkers in chronic inflammatory bowel diseases: results of a multicenter study. World J Gastroenterol. 2007;13(16):2312-8. doi: 10.3748/wjg.v13.i16.2312
- Conrad K, Roggenbuck D, Laass MW. Diagnosis and classification of ulcerative colitis. Autoimmun Rev. 2014;13(4-5):463-6. doi: 10.1016/j.autrev.2014.01.028
- Schulte-Pelkum J, Radice A, Norman GL, et al. Novel clinical and diagnostic aspects of antineutrophil cytoplasmic antibodies. J Immunol Res. 2014;2014:185416. doi: 10.1155/2014/185416
- Joossens S, Vermeire S, Van Steen K, et al. Pancreatic autoantibodies in inflammatory bowel disease. Inflamm Bowel Dis. 2004;10(6):771-7. doi: 10.1097/00054725-200411000-00012
- Zhou G, Song Y, Yang W, et al. ASCA, ANCA, ALCA and Many More: Are They Useful in the Diagnosis of Inflammatory Bowel Disease? Dig Dis. 2016;34(1-2):90-7. doi: 10.1159/000442934
- Laass MW, Roggenbuck D, Conrad K. Diagnosis and classification of Crohn’s disease. Autoimmun Rev. 2014;13(4-5):467-71. doi: 10.1016/j.autrev.2014.01.029
- Ferrante M, Henckaerts L, Joossens M, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut. 2007;56(10):1394-403. doi: 10.1136/gut.2006.108043
- Papp M, Altorjay I, Dotan N, et al. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol. 2008;103:665-81. doi: 10.1111/j.1572-0241.2007.01652.x
- Seow CH, Stempak JM, Xu W, et al. Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype. Am J Gastroenterol. 2009;104:1426-34. doi: 10.1038/ajg.2009.79
- Markowitz J, Kugathasan S, Dubinsky M, et al. Age of diagnosis influences serologic responses in children with Crohn’s disease: a possible clue to etiology? Inflamm Bowel Dis. 2009;15:714-9. doi: 10.1002/ibd.20831
- Rieder F, Schleder S, Wolf A, et al. Serum anti-glycan antibodies predict complicated Crohn’s disease behavior: a cohort study. Inflamm Bowel Dis. 2010;16(8):1367-75. doi: 10.1002/ibd.21179
- Somma V, Ababneh H, Ababneh A, et al. The novel Crohn’s disease marker anti-GP2 antibody is associated with ileocolonic location of disease. Gastroenterol Res Pract. 2013;2013:1-7. doi: 10.1155/2013/683824
- Däbritz J, Bonkowski E, Chalk C, et al. Granulocyte macrophage colony-stimulating factor auto-antibodies and disease relapse in inflammatory bowel disease. Am J Gastroenterol. 2013;108:1901-10. doi: 10.1038/ajg.2013.360
- Mokrowiecka A, Kumor A, Jakubczyk E, et al. The application of Montreal classification in different clinical and serological IBD subtypes. Hepatogastroenterology. 2010;57(101):787-93
- Targan SR, Landers CJ, Yang H, et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn’s disease. Gastroenterology. 2005;128(7):2020-8. doi: 10.1053/j.gastro.2005.03.046
- Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn’s disease. Gastroenterology. 2004;126(2):414-24. doi: 10.1053/j.gastro.2003.11.015
- Esters N, Vermeire S, Joossens S, et al. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn’s disease. Am J Gastroenterol. 2002; 97:1458-62. doi: 10.1111/j.1572-0241.2002.05689.x
- Ferrante M, Vermeire S, Katsanos KH, et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis. 2007;13:123-8. doi: 10.1002/ibd.20054
- Israeli E, Grotto I, Gilburd B, et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut. 2005;54:1232-6. doi: 10.1136/gut.2004.060228